Dr. Thomas E. Wagner
BA: Princeton University
PhD: Northwestern University
Dr. Thomas E. Wagner, Ph.D., is a co-founder of Perseus PCI. He is a world-renowned biomedical scientist, innovator and entrepreneur who has pioneered some of the past half-century’s most significant biomedical technologies used today in the study and elimination of cancer.
The personalized cancer immunotherapeutics deployed at Perseus are licensed by and principally based on Dr. Wagner’s research breakthroughs, which helped launch gene-based medicine and other aspects of the biotech industry.
Dr. Wagner has attracted more than $25 million in research funding and has held prestigious faculty and research positions at Cornell University College of Medicine, The Sloan Kettering Institute for Cancer Research, Ohio University, Cambridge University, Ohio Edison Biotechnology Institute, Clemson University and the Greenville Hospital System University Medical Center. He has published more than 250 books and scientific papers in highly respected peer-reviewed biomedical journals and holds more than 50 patents.
Since the 1970s, Dr. Wagner has been a partner or a principal investigator for any number of major discoveries in the conformational changes in DNA associated with gene expression. His research has advanced embryonic microsurgery and the methods in molecular biology that are used to assemble recombinant DNA molecules and direct their replication within host organisms.
More than 30 years ago, Dr. Wagner was a pioneer in the development of transgenic technology — a methodology used to study the molecular details of a wide range of human diseases. He was also among the first to develop methods of cell-based therapies.
Dr. Wagner was also a pioneer in developing vehicles for cell-based gene therapy in 1987 and was the principal developer of a highly efficient cytoplasmic T7 gene therapy vector in 1993 which achieved for the first time rapid and high levels of gene expression in cancer cells and tissues.
Since 1998, Dr. Wagner’s research has focused exclusively on the application of modern molecular and cellular biology to the development of new therapies for the treatment of cancer. He served as Director for the Oncology Research Institute of Greenville Hospital System, which is a national, award-winning leader in effectively applying advanced medical technology in the fight against cancer. Dr. Wagner was also a Director of Eternal Technologies Group Inc., based in Beijing, China, which develops, manufactures and markets advanced medical equipment and technologies used in the detection and prevention of breast cancer.
Dr. Wagner has served as a scientific advisor to the World Health Organization, to the US Congress, and to the White House of President Ronald Reagan. He has continued to lecture and keynote at major scientific conferences and congresses on innovations on biotechnology, gene transfer and cancer therapy.
Dr. Wagner has been an enthusiastic supporter and active contributor behind the unprecedented growth of biomedical research and technology on university campuses across the People’s Republic of China. He is today a Senior Examiner and Consultant of Research Grants Council, Hong Kong, which is the principal distributor of medical research funds in Hong Kong; an Advisor and Honorary Professor of Molecular Biology at Tsing Hua University, Beijing, the “MIT” and principal science, technology and engineering campus in the People’s Republic of China; and Honorary Professor of Biology at China’s leading center for genetic and biological research, the National Hydrobiology Institute in Wuhan.
Dr. Wagner is an experienced and successful entrepreneur. In addition to his contributions to Perseus PCI, he is also a cofounder of Diagnostic Hybrids, founded in 1983, which develops, manufactures and markets cellular and molecular diagnostic kits used to detect respiratory diseases, herpes infections, thyroid function, and other high value markers of disease. He a founder of the Ohio Edison Biotechnology Institute, the GHS Oncology Research Institute, and Orbis Health Solutions LLC which is a founding and funding partner of Perseus PCI.